1. Home
  2. FATE vs SCM Comparison

FATE vs SCM Comparison

Compare FATE & SCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

SELL

Current Price

$2.07

Market Cap

260.0M

Sector

Health Care

ML Signal

SELL

Logo Stellus Capital Investment Corporation

SCM

Stellus Capital Investment Corporation

HOLD

Current Price

$7.25

Market Cap

211.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
FATE
SCM
Founded
2007
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
260.0M
211.0M
IPO Year
2013
2012

Fundamental Metrics

Financial Performance
Metric
FATE
SCM
Price
$2.07
$7.25
Analyst Decision
Buy
Hold
Analyst Count
11
5
Target Price
$5.74
★ $10.13
AVG Volume (30 Days)
★ 1.1M
120.6K
Earning Date
11-16-2026
11-17-2026
Dividend Yield
N/A
★ 14.04%
EPS Growth
★ 29.88
N/A
EPS
N/A
★ 0.62
Revenue
★ $6,646,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.85
P/E Ratio
★ N/A
$11.55
Revenue Growth
N/A
★ N/A
52 Week Low
$0.95
$6.54
52 Week High
$3.23
$13.55

Technical Indicators

Market Signals
Indicator
FATE
SCM
Relative Strength Index (RSI) 43.74 48.28
Support Level $1.78 $6.83
Resistance Level $2.15 $8.92
Average True Range (ATR) 0.13 0.18
MACD 0.02 0.07
Stochastic Oscillator 60.42 77.33

Price Performance

Historical Comparison
FATE
SCM

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About SCM Stellus Capital Investment Corporation

Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm functions throughout the United States, and it generates revenue in the form of interest income on debt investments, capital gains, and distributions.

Share on Social Networks: